ADMA BIOLOGICS, INC. Deferred Revenue
ADMA BIOLOGICS, INC. (ADMA) had Deferred Revenue of $142.83 thousand as of 2021-03-31, per its 10-Q filed 2021-05-12.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2021-05-12
- 2021-03-31: Deferred Revenue, Current $142.83K.
- 2020-12-31: Deferred Revenue, Current $142.83K.
- 2020-09-30: Deferred Revenue, Current $142.83K.
- 2020-06-30: Deferred Revenue, Current $142.83K.
| Period end | Deferred Revenue, Current |
|---|---|
| 2021-03-31 | $142.83K 10-Q · filed 2021-05-12 |
| 2020-12-31 | $142.83K 10-Q · filed 2021-05-12 |
| 2020-09-30 | $142.83K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $142.83K 10-Q · filed 2020-08-05 |
| 2019-12-31 | $142.83K 10-K · filed 2021-03-25 |
| 2018-12-31 | $142.83K 10-K · filed 2020-03-13 |
| 2017-12-31 | $142.83K 10-K · filed 2019-03-13 |
| 2016-12-31 | $145.15K 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |